Evaluation of the Relationship between Various Histopathological Types of Primary Malignant Thyroid Carcinoma and Blood Groups


  • Yadgar Aziz Abdullah Medical Laboratory Department, College of Health and Medical Technology, Sulaimani Polytechnic University, Sulaimani city, Kurdistan, Iraq
  • Ali Hattem Hussein Nursing Department, College of Health and Medical Technology, Sulaimani Polytechnic University, Sulaimani city, Kurdistan, Iraq


Background: The ABO and Rh system have a great association to different kind of malignancy as mentioned in the literature. The data about prevalence of blood group with thyroid malignancies were limited in the literature; we aimed to record the relationship of different ABO and Rh blood groups with different malignant thyroid tumors. Methodology:  the demographics, ABO blood group, Rh factor, histopathological type of malignant thyroid tumors were recorded for each patient with malignant thyroid tumor (MTT); then we evaluated the association between different blood group types with different histopathological pattern. Results: Papillary thyroid carcinoma (PTC) was the most common MTT [n=46, (92%)], while all other types were uncommon, they were follicular thyroid carcinoma [(n=1) 2%], medullary thyroid carcinoma [(n=1) 2%], Hurthle cell carcinoma [(n=1) 2%] and anaplastic thyroid carcinoma [(n=1) 2%]., the blood group A with Rh positive was the most frequent [n= 17, (34%)], , the O+ve was [n=15 (30%)], B+ve [n=10 (20%)], while AB-ve [n=3 (6%)] while a small number was Rhesus negative. The A+ve blood group was the commonest blood group in PTC patients (34.8%), followed by O+ve (30.4%). Conclusion: Blood group A+ve is the most frequently reported among cases of papillary thyroid carcinoma, which is the most common MTT.


Wartofsky L, Van Nostrand D. Thyroid cancer: a comprehensive guide to clinical management: Springer; 2006.

Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carcinoma: A population‐based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) Program 1973–1991. Cancer: Interdisciplinary International Journal of the American Cancer Society. 1997;79(3):564-73.

Yang H, Yan J. A systematic review of prognosis of ABO blood group and rhesus factor on outcomes in patients with bladder cancer. Medicine. 2022;101(39):e30893.

Wang J, García-Bailo B, Nielsen DE, El-Sohemy A. ABO genotype,‘blood-type’diet and cardiometabolic risk factors. PloS one. 2014;9(1):e84749.

Liumbruno GM, Franchini M. Hemostasis, cancer, and ABO blood group: the most recent evidence of association. Journal of thrombosis and thrombolysis. 2014;38:160-6.

Kim D-S, Scherer PE. Obesity, diabetes, and increased cancer progression. Diabetes & metabolism journal. 2021;45(6):799-812.

Hovinga ICK, Koopmans M, de Heer E, Bruijn JA, Bajema IM. Change in blood group in systemic lupus erythematosus. The Lancet. 2007;369(9557):186-7.

Edition S, Edge S, Byrd D. AJCC cancer staging manual. AJCC cancer staging manual. 2017.

Lang TA, Secic M. How to report statistics in medicine: annotated guidelines for authors, editors, and reviewers: ACP Press; 2006.

Habibzadeh F. Common statistical mistakes in manuscripts submitted to biomedical journals. European Science Editing. 2013;39(4):92-4.

Habibzadeh F. Statistical data editing in scientific articles. Journal of Korean medical science. 2017;32(7):1072-6.

Karhu D, Vanzieleghem M. Significance of digits in scientific research. AMWA J. 2013;28(2):58-60.

Jonklaas J, Nogueras-Gonzalez G, Munsell M, Litofsky D, Ain K, Bigos S, et al. The impact of age and gender on papillary thyroid cancer survival. The Journal of Clinical Endocrinology & Metabolism. 2012;97(6):E878-E87.

Rahbari R, Zhang L, Kebebew E. Thyroid cancer gender disparity. Future Oncology. 2010;6(11):1771-9.

Yager J, Leihr J. Molecular mechanisms of estrogen carcinogenesis. Annual review of pharmacology and toxicology. 1996;36(1):203-32.

Lee M, Chen G, Vlantis A, Tse G, Leung B, Van Hasselt C. Induction of thyroid papillary carcinoma cell proliferation by estrogen is associated with an altered expression of Bcl-xL. The Cancer Journal. 2005;11(2):113-21.

Zeng Q, Chen G, Vlantis A, Van Hasselt C. Oestrogen mediates the growth of human thyroid carcinoma cells via an oestrogen receptor–ERK pathway. Cell Proliferation. 2007;40(6):921-35.

Ortega J, Sala C, Flor B, Lledo S. Efficacy and cost-effectiveness of the UltraCision® harmonic scalpel in thyroid surgery: an analysis of 200 cases in a randomized trial. Journal of Laparoendoscopic & Advanced Surgical Techniques. 2004;14(1):9-12.

Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2009;115(16):3801-7.

Moysich KB, Menezes RJ, Michalek AM. Chernobyl-related ionising radiation exposure and cancer risk: an epidemiological review. The Lancet Oncology. 2002;3(5):269-79.

Cardis E, Kesminiene A, Ivanov V, Malakhova I, Shibata Y, Khrouch V, et al. Risk of thyroid cancer after exposure to 131 I in childhood. Journal of the National Cancer Institute. 2005;97(10):724-32.

Parad MT, Fararouei M, Mirahmadizadeh AR, Afrashteh S. Thyroid cancer and its associated factors: A population‐based case‐control study. International Journal of Cancer. 2021;149(3):514-21.

LeClair K, Bell KJ, Furuya-Kanamori L, Doi SA, Francis DO, Davies L. Evaluation of gender inequity in thyroid cancer diagnosis: differences by sex in US thyroid cancer incidence compared with a meta-analysis of subclinical thyroid cancer rates at autopsy. JAMA Internal Medicine. 2021;181(10):1351-8.

Franceschi S, Boyle P, Maisonneuve P, La Vecchia C, Burt AD, Kerr DJ, et al. The epidemiology of thyroid carcinoma. Critical reviews in oncogenesis. 1993;4(1):25-52.

Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. Jama. 2006;295(18):2164-7.

Zhu C, Zheng T, Kilfoy BA, Han X, Ma S, Ba Y, et al. A birth cohort analysis of the incidence of papillary thyroid cancer in the United States, 1973–2004. Thyroid. 2009;19(10):1061-6.

Howlader N, Noone A, Krapcho M, Miller D, Bishop K, Altekruse S, et al. SEER Cancer Statistics Review, 1975–2013. Bethesda, MD: National Cancer Institute; 2016. 2016.

Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. The Lancet. 2016;388(10061):2783-95.

Bonnefond S, Davies TF. Thyroid cancer—risks and causes. Journal-Thyroid Cancer—Risks and Causes. 2014.

Reid ME, Mohandas N, editors. Red blood cell blood group antigens: structure and function. Seminars in hematology; 2004: Elsevier.

Tam AA, Özdemir D, Fakı S, Bilginer MC, Ersoy R, Çakır B. ABO blood groups, Rh factor, and thyroid cancer risk: to ‘B’or not to ‘B’. Endocrine research. 2020;45(2):137-46.

Franchini M, Liumbruno GM. ABO blood group: old dogma, new perspectives. Clinical Chemistry and Laboratory Medicine (CCLM). 2013;51(8):1545-53.

Edgren G, Hjalgrim H, Rostgaard K, Norda R, Wikman A, Melbye M, et al. Risk of gastric cancer and peptic ulcers in relation to ABO blood type: a cohort study. American journal of epidemiology. 2010;172(11):1280-5.

Hakomori S-i. Antigen structure and genetic basis of histo-blood groups A, B and O: their changes associated with human cancer. Biochimica et Biophysica Acta (BBA)-General Subjects. 1999;1473(1):247-66.

Zhang B-L, He N, Huang Y-B, Song F-J, Chen K-X. ABO blood groups and risk of cancer: a systematic review and meta-analysis. Asian Pacific Journal of Cancer Prevention. 2014;15(11):4643-50.

Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860-7.

Li C, Xu F, Huang Q, Han D, Zheng S, Wu W, et al. Nomograms for differentiated thyroid carcinoma patients based on the eighth AJCC staging and competing risks model. JNCI Cancer Spectrum. 2021;5(3):pkab038.

Kakudo K, Tang W, Ito Y, Mori I, Nakamura Y, Miyauchi A. Papillary carcinoma of the thyroid in Japan: subclassification of common type and identification of low risk group. Journal of clinical pathology. 2004;57(10):1041-6.